SAINT® TMS vs tDCS for Depression: Mechanism, Evidence & FDA Status
SAINT® TMS and tDCS (transcranial direct current stimulation) are non-invasive electrical/magnetic brain-based therapies that differ across clinical indications, mechanisms, speed, and delivery. In December 2025, the FDA approved the first prescription at-home tDCS device (Flow Neuroscience FL-100) for moderate to severe MDD in adults who are not treatment-refractory, delivering low-intensity current over 10 weeks at home. SAINT® is an FDA-cleared in-clinic protocol (K220177) specifically indicated for treatment-resistant depression, using individualized resting-state fMRI to deliver 50 high-intensity magnetic stimulation sessions in just 5 days.
Key takeaways
- FDA Status: Flow tDCS was FDA-approved in December 2025 for non-treatment-refractory MDD; SAINT® is FDA-cleared for treatment-resistant depression with Breakthrough Device designation.
- Target Population: tDCS is intended for patients who have not failed multiple medications; SAINT® is built for treatment-resistant depression after medication failure.
- Timeline: SAINT® finishes in 5 consecutive business days (10 sessions/day); tDCS requires home sessions over 10 weeks.
- Targeting: SAINT® uses individualized 3T resting-state fMRI targeting sgACC-dlPFC connectivity; tDCS uses broad scalp electrode montages.
- Mechanism: SAINT® depolarizes prefrontal neurons with high-intensity magnetic pulses; tDCS applies sub-threshold direct current (1–2 mA) to modulate excitability.
- Cost: At-home tDCS headsets cost ~$500; in-clinic SAINT® starts at $25,000 for the full physician-supervised week including MRI.
Quick Summary: Two Different Brain Technologies for Two Different Patient Profiles
If you are researching non-drug options for depression, you will encounter both tDCS and TMS. Because both involve wearing a headset or coil, patients often wonder if they are interchangeable or if an inexpensive home tDCS device is a 'budget alternative' to SAINT®.
They are not the same technology, nor are they indicated for the same patients. tDCS uses micro-currents to shift baseline neuronal excitability over months at home, while SAINT® uses high-powered magnetic pulses to actively fire prefrontal circuits over 5 days in a specialized medical clinic.
Side-by-Side Comparison: SAINT® vs Prescription tDCS
The table below compares the clinical parameters of SAINT® (on the Magnus Neuromodulation System) and prescription tDCS (Flow FL-100):
| Parameter | SAINT® Accelerated TMS | Prescription tDCS (Flow FL-100) |
|---|---|---|
| Primary Mechanism | High-intensity magnetic pulses causing neuronal depolarization in dlPFC | Low-intensity electrical direct current (1–2 mA) modulating resting membrane potential |
| FDA Regulatory Status | FDA-cleared (510(k) K220177) with Breakthrough Device designation | FDA-approved (December 8, 2025) as prescription at-home medical device |
| FDA Indication | Major Depressive Disorder in adults with inadequate response to prior antidepressants (TRD) | Moderate to severe MDD in adults 18+ who are not considered treatment-refractory to medication |
| Treatment Duration | 5 consecutive days (10 sessions/day, 50-min intervals; ~50 sessions total) | 10 weeks (30-minute sessions, typically 5x/week for 3 weeks then 2–3x/week) |
| Setting & Oversight | In-clinic outpatient suite under direct psychiatric/medical supervision | Self-administered at home under remote prescription/app monitoring |
| Targeting Precision | Individualized 3T resting-state fMRI targeting sgACC-dlPFC functional connectivity | Standardized scalp placement (F3/Fp2 broad sponge electrodes) |
| Pivotal Clinical Trial | Double-blind RCT: 79% remission at week 4 (Cole et al., Am J Psychiatry 2022) | Double-blind RCT: 58% remission at week 10 in Nature Medicine (Woodham et al., 2024) |
| Approximate Cost | Starts at $25,000 (all-inclusive 5-day protocol, fMRI, and medical oversight) | ~$500 device purchase or monthly subscription model |
Mechanism: Magnetic Stimulation vs Direct Current
The most critical physiological distinction is stimulation intensity and threshold:
• Transcranial Magnetic Stimulation (TMS / SAINT®): A magnetic coil generates focused magnetic field pulses (~1.5 to 3 Tesla, similar in strength to an MRI scanner) that pass unattenuated through skin and skull. By Faraday's law of induction, this generates an intracranial electrical field that triggers action potentials (neuronal depolarization) in targeted pyramidal neurons in the left dorsolateral prefrontal cortex. Because SAINT® repeats this across 10 spaced sessions daily, it induces robust, lasting long-term potentiation (LTP)-like synaptic plasticity.
• Transcranial Direct Current Stimulation (tDCS): Two wet sponge electrodes on the scalp pass a constant low-voltage direct current (typically 1 to 2 mA) between an anode and a cathode. Much of the electrical current shunts across the scalp. The small fraction reaching the cortex does not cause neurons to fire action potentials; instead, it creates a subtle shift in the neuronal resting membrane potential—sub-threshold modulation that slightly increases (under the anode) or decreases (under the cathode) spontaneous firing rates.
Targeting: Personalized fMRI vs Standard Scalp Montage
Brain connectivity varies substantially between individuals with depression. In traditional TMS and tDCS, electrodes or coils are positioned using scalp measurements (such as the 10-20 EEG system).
SAINT® is unique in requiring a preliminary 3T functional MRI. The Magnus Medical algorithm calculates the individual voxels in the left prefrontal cortex that exhibit maximal negative correlation (anti-correlation) with the subgenual anterior cingulate cortex (sgACC)—a deep emotional regulation node that is consistently hyperactive in treatment-resistant depression. Stimulating this precise personalized target is why the Stanford trial achieved 79% remission (Cole et al., 2022).
tDCS uses fixed head-strap measurements. While convenient for home use, it cannot account for individual anatomical or functional connectivity differences.
Who Each Treatment Fits Best
Choose Prescription tDCS if: You have moderate depression, have had good results from or have not yet failed multiple medications, prefer an affordable at-home approach, and can consistently commit to 30-minute daily sessions for 10 weeks.
Choose SAINT® Accelerated TMS if: You have treatment-resistant depression (two or more failed antidepressant trials), cannot wait 6 to 10 weeks for symptom relief, need a rapid clinical intervention within a single week, or have suffered intolerable systemic medication side effects. Take our candidacy check or explore SAINT® TMS cost.
Understanding SAINT® TMS: How It Works & What to Expect
SAINT® is an FDA-cleared treatment for adults with major depressive disorder who have not improved on antidepressants in the current episode. These videos explain how it works and how it differs from conventional TMS.
SAINT® is an FDA-cleared, fMRI-guided form of TMS developed at Stanford. Most patients complete treatment in one week — not the six weeks standard TMS requires.
Follow a real patient through the five-day SAINT® treatment week
Is SAINT® TMS Right for You?
Tried antidepressants without enough relief? SAINT® TMS is an FDA-cleared, fMRI-guided treatment for adults with major depressive disorder who have not improved enough with antidepressant medication.
SAINT® uses a personalized brain target and delivers treatment over five consecutive days. It differs from standard TMS in its targeting approach, treatment schedule, and research background. In a small randomized trial, 11 of 14 people receiving active treatment reached remission at the four-week assessment, compared with 2 of 15 receiving sham treatment. Results vary, and a five-day treatment course does not guarantee remission in five days.
How SAINT® Works and How It Differs From Conventional TMS
SAINT® is an FDA-cleared treatment for adults with major depressive disorder who have not improved on antidepressants in the current episode. This video explains how it works, and how it differs from conventional TMS.
Conventional TMS usually means about 30 visits over 6 to 9 weeks. SAINT is five visits over five days.
What makes it different: SAINT® uses an fMRI brain scan to personalize the stimulation target to your individual brain. A 45-minute scan maps your brain and identifies the specific circuit linked to depression. Treatment is then delivered as ten 10-minute sessions per day, with 50-minute breaks between them, across five consecutive days.
In clinical trials, 79% of participants reached remission, with an average of 2.6 days to remission. SAINT is generally well tolerated; the most common side effects reported were mild headache and temporary scalp discomfort at the treatment site.
SAINT® at Neuro Wellness TMS Centers of America
Coral Springs, Florida
Free benefits check · Self-pay options available
Call or Text: 954-827-9793
Sources: Cole et al., American Journal of Psychiatry 2020;177:716-726 and 2022;179(2):132-141. magnusmedical.com/depression-therapy. PubMed 34711062. FDA 510(k) K220177.
Insurance coverage for SAINT is currently limited and varies by plan. Individual results may vary. This video is educational and is not medical advice. Talk to a qualified clinician about whether SAINT is appropriate for you. If you are in crisis, call or text 988.
Frequently Asked Questions
Is tDCS FDA-approved for depression?
Yes. On December 8, 2025, the U.S. FDA approved the first prescription at-home tDCS device (the Flow Neuroscience FL-100) for the treatment of moderate to severe major depressive disorder in adults aged 18 and older who are not considered treatment-refractory to medication. Older blanket statements claiming tDCS has no FDA approval are outdated. However, other consumer tDCS headsets sold directly without a prescription remain non-FDA-approved wellness products.
How does tDCS work compared to SAINT® TMS?
The mechanisms are fundamentally different. tDCS delivers a very low-intensity electrical direct current (typically 1 to 2 milliamps) through scalp electrodes to gently increase cortical excitability, but it does not depolarize neurons directly. SAINT® delivers high-intensity pulsed magnetic fields that induce intracranial electrical currents strong enough to depolarize neurons in the prefrontal cortex, targeted to individual functional MRI connectivity with the subgenual anterior cingulate cortex (sgACC).
Which treatment works faster, SAINT® or tDCS?
SAINT® is significantly faster in calendar time: the complete 50-session protocol is completed in 5 consecutive days (Monday through Friday, 10 sessions per day). In contrast, prescription tDCS involves 30-minute sessions performed daily or near-daily over 10 weeks (several months) at home.
Is tDCS appropriate if I have treatment-resistant depression?
The FDA approval for Flow tDCS is specifically indicated for patients who are 'not considered treatment refractory to medication' (either as monotherapy or adjunctive to an antidepressant). SAINT®, on the other hand, is specifically cleared for treatment-resistant major depression—adults who have failed to achieve satisfactory improvement from prior antidepressants in the current episode. Patients with multi-medication resistance typically require in-clinic neuromodulation like SAINT® or standard TMS.
What is the cost difference between tDCS and SAINT®?
Prescription tDCS headsets like Flow retail for approximately $500 (or monthly subscriptions), making it an accessible home option. SAINT® at Neuro Wellness starts at $25,000 for the complete protocol, reflecting individualized 3T resting-state fMRI targeting, medical director oversight, private clinical suites, and 50 intensive sessions over five days. Insurance coverage for SAINT® is plan-specific and verified on a case-by-case basis.
Cited Research
- 1. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression: a double-blind randomized controlled trial. Am J Psychiatry. 2022;179(2):132-141.
- 2. Woodham RD, Rimmer RM, Young AH, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomised sham-controlled trial. Nature Medicine. 2024;30(3):887-895.
- 3. U.S. Food and Drug Administration. Approval of Flow Neuroscience FL-100 Transcranial Direct Current Stimulation System for Major Depressive Disorder (Dec 8, 2025).
- 4. U.S. Food and Drug Administration. 510(k) Premarket Notification K220177 — Magnus Medical SAINT Neuromodulation System.
Important Safety Information
SAINT® TMS and tDCS are non-invasive treatments. SAINT® carries a low risk of seizure (<0.1%) and common mild scalp discomfort or headache. tDCS side effects typically include mild skin tingling, redness, or itching under electrode pads; improper use or re-using dried pads can cause skin burns. Neither treatment guarantees clinical remission. If you are experiencing suicidal thoughts, call or text 988.
SAINT® is delivered only by verified providers on the Magnus Medical system. Programs described as SAINT “alternatives”, “equivalents” or “fMRI-guided accelerated TMS” are not SAINT®, are not affiliated with us, and SAINT® results do not apply to them. Read our SAINT® disclaimer.
Compare Brain Stimulation Options with Our Clinical Team
Speak with our clinical team. A free consultation is the best way to get answers specific to your situation.
SAINT® is a registered trademark of Stanford University, exclusively licensed to Magnus Medical, Inc. Flow FL-100 is a registered trademark of Flow Neuroscience AB. NWCOA is an independent clinic in Coral Springs, FL.
Related Patient Education
SAINT® vs Traditional TMS
Compare 5-day accelerated SAINT® to 6-week daily TMS
Fast Depression Treatment Options
Overview of fast-acting options: SAINT®, ketamine, SPRAVATO®, and TMS
What Is SAINT® TMS?
Comprehensive guide to fMRI guidance, 5-day protocol, and evidence
SAINT® TMS Cost
Transparent self-pay pricing, insurance verification, and financing
SAINT® vs Neurofeedback
Compare magnetic stimulation to EEG biofeedback brain training